Archive
Home / Media Centre / Archive
Here you can find the archive of all Press Releases prior to 2022
Filter by date:
Showing 1107 press releases before 2022
-
AstraZeneca’s triple-combination therapy approved in China for patients with COPD
-
Enhertu (trastuzumab deruxtecan) approved in the US for HER2-positive unresectable or metastatic breast cancer following two or more prior anti-HER2 based regimens
-
AstraZeneca divests rights to Arimidex and Casodex in Europe and certain additional countries
-
Lynparza recommended by FDA advisory committee for 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer
-
Agreement with Cheplapharm for rights to Seroquel and Seroquel XR in Europe and Russia completed
-
Imfinzi approved in China for the treatment of unresectable, Stage III non-small cell lung cancer based on the Phase III PACIFIC trial
-
Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial
-
Calquence significantly prolonged the time patients lived without disease progression or death in previously untreated chronic lymphocytic leukaemia
-
Lynparza approved in China as a 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer
-
AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada
Latest articles and press releases
All of our latest press releases and articles are available to explore
